The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Clinical trial NCT07187674 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07187674
- Sponsor
- Harbin Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-30
- Primary completion
- 2028-06-15
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.